Nucleic acid molecule conjugate having prolonged in vivo half-life
OwnerGe ZHANG, Yixin HEinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of biomedicine. In particular, the present invention relates to a nucleic acid molecule conjugate with extended in vivo half-life, wherein the nucleic acid molecule is conjugated to a fatty acid and a coumarin derivative. More specifically, the nucleic acid molecule is an aptamer, in particular an aptamer against sclerostin.
Claims36
A nucleic acid molecule conjugate with extended in vivo half-life, wherein the nucleic acid molecule is conjugated to a fatty acid and/or a coumarin derivative.
The nucleic acid molecule conjugate of any one of claims 1-3, wherein the fatty acid, such as dodecanedioic acid, is conjugated to the 5′ end of the nucleic acid molecule;
- or the coumarin derivative, such as 4-hydroxycoumarin, is conjugated to the 5′ end of the nucleic acid molecule;
- or the fatty acid, such as dodecanedioic acid, and the coumarin derivative, such as 4-hydroxycoumarin, are conjugated to the 5′ end of the nucleic acid molecule.
A aptamer conjugate against sclerostin, which comprises an aptamer against sclerostin conjugated to a fatty acid and/or a coumarin derivative,
- wherein the aptamer comprises
- i) a nucleotide sequence having at least about 90% identity, at least about 91% identity, at least about 90% identity, about 92% identity, at least about 93% identity, at least about 94% identity, or at least about 95% identity to any one of SEQ ID NOs:
- 1-17, or
- ii) at least 30, at least 35, at least 40, at least 45, at least 50, or more consecutive nucleotides within any one of SEQ ID NOs:
- 1-17,
- wherein the aptamer specifically binds to sclerostin.
Dependencies are inferred from the claim text.